• Updated May 2017: Expert Insights

    In situations of major bleeding anticoagulation reversal is often essential, but how should reversal be managed in these patients? Join our experts as they discuss best practice.

  • Factor Xa and IIa Inhibitors

    Explore the various different factor Xa and IIa inhibitors such as apixaban and dabigatran, citing recent clinical trial data.

  • Publications Digest

    Read several in-depth summaries on oral anticoagulation reversal in the Publications Digest section, dedicated to providing analysis and commentary of recent published literature.

  • Symposia Media Library

    Video and slide presentations are available from the annual congresses of ISICEM and ISTH, providing valuable insight from world-leading experts into new and emerging techniques in anticoagulation reversal.

  • Disease Management

    Discover methods for the management of bleeding risks associated with oral anticoagulation treatments. What diagnositic tests can be used and how can bleeding be controlled?

 

Oral Anticoagulation Reversal Knowledge Centre

Welcome to the Oral Anticoagulation Reversal Knowledge Centre. This educational resource is designed to help healthcare professionals diagnose, manage and treat bleeding in patients taking anticoagulants.

The aim of this Knowledge Centre is to give an overview of blood coagulation, anticoagulation, bleeding risk and the various methods for the management and treatment of bleeding in patients taking anticoagulants. Details of blood coagulation factors II, VII, IX and more; the coagulation cascade; haemorrhagic risk assessment, using the international normalised ratio; the factor Xa inhibitors rivaroxaban, edoxaban or apixaban; the factor IIa (thrombin) inhibitor dabigatran; the risks of warfarin treatment; current national and international guidelines; the use of fresh frozen plasma to reverse vitamin K antagonist (VKA) anticoagulation; plasma and rVIIA; and details of the anticoagulation reversal agents idarucizumab, andexanet alpha and ciraparantag are all included in this section.

The Oral Anticoagulants section goes on to provide information on the options available for oral anticoagulation, such as factor Xa and IIa inhibitors. Details of the effects that VKAs can have on patients with atrial fibrillation, heart failure, valvular heart disease, venous thromboembolism and transient ischaemic attacks; the use of paracetamol and an adjuvant therapy; how the CYP2C9 and VKORC1 genes affect blood coagulation; and details of non-vitamin K oral anticoagulants, such as factor Xa inhibitors, rivaroxaban, apixaban, edoxaban, and the factor IIa inhibitor dabigatran are all included in this section.

Disease Management

Disease Management

Discover how blood coagulates, how drugs work to reverse coagulation, what diagnostic tests are used to assess bleeding risk and how to treat anticoagulant-associated bleeding.

Oral Anticoagulants

Oral Anticoagulants

With oral vitamin K antagonists and non-vitamin K oral anticoagulants being covered, you'll be able to understand the merits and drawbacks of individual treatments in detail.

Publications Digest

Publications Digest

Read several in-depth summaries in the Publications Digest section, an area dedicated to providing analysis and commentary of related published literature.

Symposia Media Library

Symposia Media Library

Video and slide presentations are available from the annual congresses of ISICEM and ISTH, providing valuable insight from world-leading experts into new and emerging techniques in anticoagulation reversal.

Expert Insights

Expert Insights

In situations of major bleeding anticoagulation reversal is often essential, but how should reversal be managed in these patients? Join our experts as they discuss best practice.

Resources

Resources

Read key papers, view and download educational slides concerning key phase III trials and attend one of the events in our upcoming events calendar.


 

Login/ Register Maximise Minimise

Alternatively login via